News & Updates
Filter by Specialty:
Investigational DP2 antagonist strikes out in eosinophilic asthma
13 Mar 2022
The prostaglandin D2 receptor 2 (DP2) antagonist GB001 does not appear to significantly lower the risk of disease worsening in patients with moderate-to-severe eosinophilic asthma, according to data from a phase IIb trial.
Investigational DP2 antagonist strikes out in eosinophilic asthma
13 Mar 2022Shorter antibiotic regimen enough in kids with pneumonia?
10 Mar 2022
byRoshini Claire Anthony
Children with non-severe community-acquired pneumonia (CAP) may benefit from a 5-day antibiotic regimen compared with the current standard regimen of 10 days, according to results of the US-based SCOUT-CAP trial.
Shorter antibiotic regimen enough in kids with pneumonia?
10 Mar 2022Delamanid-based regimens work against multidrug-resistant tuberculosis
10 Mar 2022
The use of delamanid-containing regimens is safe and effective in the management of multidrug-resistant tuberculosis (MDR-TB), with high culture conversion and treatment success rates despite extensive resistance patterns, according to the results of a meta-analysis.